Galápagos receives €2.5 million milestone from Lilly

Galápagos NV said that it has reached a milestone in its collaboration with Eli Lilly to develop new medicines for osteoporosis triggering a payment of €2.5 million.  This brings total payments to it from the collaboration to €3.9 million.